The positive topline results from our Phase 3 Emerge clinical trial represent more than a company milestone, they reflect growing momentum toward potential new treatment possibilities for people living with major depressive disorder (MDD).
Hear from Emerge Principal Investigator and practicing clinical psychologist, John Sonnenberg, Ph.D., who shares his perspective on the significance of these findings and how the growing body of evidence surrounding psychedelics like pharmaceutical LSD is fueling excitement and optimism across the field of psychiatry.
Check out our recent press release to learn more about the Emerge Phase 3 topline data: https://t.co/MO7zkV9k02
#MentalHealth #DefiniumTherapeutics #Psychedelics #HealthcareInnovation #MDD #Depression